None listed
Conditions
Brief summary
The purpose of this study was to assess the amounts of particular immune cells in tissue around a specific type of breast cancer in patients whose cancer had returned. The results were compared to the amounts of these immune cells in tissue from patients with the same type of breast cancer whose cancer had not returned to evaluate whether these immune cells could help to predict which cancers were more likely to return.
Interventions
Data prospectively collected from January 2000 to June 2013 at a single centre at the Mount Hospital in Perth.
Archival formalin-fixed, paraffin embedded samples one each of primary tumour and one of involved and uninvolved axillary nodes from 60 patients with luminal B early breast cancer who had experienced an invasive breast cancer event reviewed retrospectively. These were compared with Formalin-Fixed Paraffin-Embedded (FFPE) samples of one each from primary tumour and one from axillary no
Data prospectively collected from January 2000 to June 2013 at a single centre at the Mount Hospital in Perth. Archival formalin-fixed, paraffin embedded samples one each of primary tumour and one of involved and uninvolved axillary nodes from 60 patients with luminal B early breast cancer who had experienced an invasive breast cancer event reviewed retrospectively. These were compared with Formalin-Fixed Paraffin-Embedded (FFPE) samples of one each from primary tumour and one from axillary nodes from a control group of 60 age and stage-matched patients treated in the same era who remained disease-free. Samples were examined for biomarkers identifying effector and suppressor immune cells and compared between the two groups. Participants were followed up per standard of care and data were collected as per standard of care as this study was a retrospective review of data collected propsectively as per standard of care (every 3 months for 2 years, 6 monthly for the following three years and then every year after that)
Sponsors
Breast Cancer Research Centre - WA
Eligibility
Sex/Gender
All
Age
44 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
Patients with Stage I, II and III breast cancer managed by the Principal Investigator between January 2000 to June 2013 Luminal B disease Patient aged between 45 - 55 years of age at time of diagnosis Adequate tissue from primary breast tissue and axillary node for evaluation Follow-up for minimum of 12 months from diagnosis
Exclusion criteria
Patient lost to follow-up prior to 12 months Patient non-compliant with recommended local or systemic adjuvant therapy Luminal A breast cancer as defined as any histological type invasive carcinoma which is grade 1 and HER2 negative Contralateral breast cancer in the absence of loco-regional relapse and/or metastatic relapse will not be regarded as a breast cancer event .Comorbidities which may be associated with altered immune function: rheumatoid arthritis, autoimmune illness, HIV-associated illness. Other malignancies with the exception of non-melanomatous skin cancer, which were managed by surgical excision or topical cryotherapy in the past Previous exposure to cytotoxic or immunotherapy. Previous radiation therapy
Outcome results
None listed